top of page

ASCO 2026: Summit Therapeutics' Co-CEO and Chief Strategy Officer discuss the HARMONi-6 ASCO data release for the PD-1xVEGF bi-specific antibody Ivonescimab

  • 22 hours ago
  • 1 min read

Maky Zanganeh and Dave Gancarz share their take on the result, which at the topline showed that Ivonescimab plus chemo reduced the risk of death by 34% vs the PD-1 Tislelizumab plus chemo, and they are given the opportunity to respond to some of the pushback heard around McCormick Place.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page